Health

‘Sick to My Stomach’: Trump Distorts Facts on Autism, Tylenol, and Vaccines, Scientists Say

Published

2 months ago

September 30, 2025

Kaiser Health News

By Amy Maxmen

Ann Bauer, a researcher who studies Tylenol and autism, felt queasy with anxiety in the weeks leading up to the White House’s much-anticipated autism announcement.

In August, Bauer and her colleagues published an analysis of 46 previous studies on Tylenol, autism, and attention-deficit/hyperactivity disorder. Many found no link between the drug and the conditions, while some suggested Tylenol might occasionally exacerbate other potential causes of autism, such as genetics.

Bauer, an epidemiologist at the University of Massachusetts-Lowell, and her team called for more judicious use of the drug until the science is settled.

On Monday, President Donald Trump stood beside Health and Human Services Secretary Robert F. Kennedy Jr. for what he called a “historic” announcement on autism. “If you’re pregnant, don’t take Tylenol, and don’t give it to the baby after the baby is born,” Trump said. “There are certain groups of people that don’t take vaccines and don’t take any pills that have no autism,” he added, without providing evidence. “They pump so much stuff into those beautiful little babies, it’s a disgrace.”

A fact sheet released alongside the White House briefing cited Bauer’s analysis. But she was alarmed by Trump’s comments. If prenatal Tylenol has any association, which it may not, it would help account for only a fraction of cases, she said. Further, research has not deeply examined Tylenol risks in young children, and many rigorous studies refute a link between vaccines and autism.

Bauer worries such statements will cut both ways: People may put themselves at risk to avoid vaccines and Tylenol, the only safe painkiller for use during pregnancy. And she frets that scientists might outright reject her team’s measured concerns about Tylenol in a backlash against misleading remarks from Trump and other members of his “Make America Healthy Again” movement.

“I’m really concerned about how this message is going to play out,” she said. “It’s a sound-bite universe, and everyone wants a simple solution.”

Autism experts at the Centers for Disease Control and Prevention were neither consulted for the White House’s long-awaited autism announcement nor asked to review a draft of the findings and recommendations, CDC scientists told KFF Health News, which agreed not to identify them because they fear retaliation.

“Typically, we’d be asked to provide information and review the report for accuracy, but we’ve had absolutely no contact with anyone,” one CDC researcher said. “It is very unusual.”

Trump and Kennedy promised this year that under their leadership the federal government would swiftly figure out what causes autism. Scientists who work in the field have been skeptical, noting that decades of research has shown that no single drug, chemical, or other environmental factor is strongly linked to the developmental disorder. In addition, both Trump and Kennedy have repeated the scientifically debunked notion that childhood vaccines may cause autism.

Helen Tager-Flusberg, director of the Center for Autism Research Excellence at Boston University, called Trump’s comments dangerous. Fevers can harm the mother and the developing fetus, she said, adding that fevers are more strongly associated with autism than Tylenol.

In an emailed response to queries, HHS spokesperson Andrew Nixon said, “We are using gold-standard science to get to the bottom of America’s unprecedented rise in autism rates.”

White House spokesperson Kush Desai wrote, “President Trump pledged to address America’s rising rate of autism, and to do so with Gold Standard Science.”

Had CDC scientists been allowed to brief Kennedy, they say they would have cautioned that simple fixes won’t make a dent in the number of autism cases in the United States: As many as 1 in 31 8-year-old children had autism spectrum disorder in 2022.

Systemic changes, such as regulations on air pollution, which has been linked to asthma and developmental disabilities including autism, and assistance for parents of disabled children, could improve lives for far more Americans with autism and other conditions than actions taken by the Trump administration on Sept. 22, researchers say.

One federal action is to consider updating the label on Tylenol and to “encourage clinicians to exercise their best judgment in use of acetaminophen for fevers and pain in pregnancy by prescribing the lowest effective dose for the shortest duration.” The American College of Obstetricians and Gynecologists already recommends acetaminophen “as needed, in moderation, and after consultation with a doctor.”

‘Political Crusade’

Despite Kennedy’s many years of speaking about autism, he rarely cites credible autism research or expert recommendations, Tager-Flusberg said. Instead, Kennedy repeats fringe, scientifically debunked theories linking vaccines to autism, despite rigorous studies published in peer-reviewed journals that refute a link.

At the Sept. 22 briefing, Trump said he spoke with Kennedy about autism 20 years ago: “We understood a lot more than a lot of people who studied it,” he said. Ahead of Trump’s first term in 2017, Kennedy said he met with the president to consider a commission on vaccine safety and autism. It didn’t happen then. But soon after Kennedy was confirmed as health secretary, he called autism “preventable,” pointed to “environmental toxins,” and contradicted the results of a CDC study finding that the main driver of rising autism diagnoses was that doctors increasingly recognize the disorder.

At a televised Cabinet meeting in April, Kennedy told Trump, “By September, we will know what has caused the autism epidemic and we’ll be able to eliminate those exposures.”

“You stop taking something, you stop eating something, or maybe it’s a shot,” Trump replied.

“He is on a political crusade,” Tager-Flusberg said of Kennedy, adding that vaccines, Tylenol, aluminum, and food dyes make for simple targets to rally against. “We know genetics is the most significant risk factor,” she said, “but you can’t blame Big Pharma for genetics, and you can’t build a political movement on genetics research and ride to victory.”

“RFK makes our work harder,” said Peter Hotez, a vaccine researcher and the author of a book about his autistic daughter, “Vaccines Did Not Cause Rachel’s Autism.” He said the book stemmed from conversations with Kennedy in 2017, in which Hotez shared studies pinpointing more than a hundred genes linked to autism, and research into the complex interplay between genetics, biological processes, and things that children and fetuses encounter during development.

“I sat down with him and explained what the science says, but he was unwilling or incapable of thinking deeply about it,” Hotez said. “He is extremely careless.”

In addition to its focus on Tylenol, the White House said it would move to update “prescribing information” on leucovorin — a medication related to the B vitamin folate — to reflect its use as an autism treatment. A small clinical trial in 2012-13 suggested the drug may help treat language problems in some children with autism. Tager-Flusberg said the findings warrant further study but clarified these were “old data, not a breakthrough.”

Likewise, studies finding a modest association between autism and prolonged Tylenol use were published years ago. Researchers have suggested the medicine might occasionally exacerbate factors associated with autism, such as genetics and oxidative stress, a biological condition that occurs for a variety of reasons that scientists are still unraveling.

Still, these studies couldn’t rule out the possibility that fevers prompting women to take Tylenol, rather than the medicine itself, might instead be to blame. Fevers and infections — including those prevented by vaccines — have also been linked to autism.

Nonetheless, Bauer’s recommendation would be to pause before taking acetaminophen while pregnant — blanket advice that doctors give for all medications during that period, but which may be ignored. “Try to alleviate discomfort in some other ways, like with a cold compress, hydration, or massage, before taking it,” Bauer said.

She welcomed the White House’s motion to consider labeling Tylenol to emphasize judicious use of the drug but worries about how the MAHA movement might distort a careful message. On Sept. 2, the right-wing news outlet One America News Network posted an interview with newly appointed CDC vaccine adviser Robert Malone, writing that Malone “speculates RFK Jr. may have an important announcement this month regarding a potential link between Tylenol, multiple vaccinations and autism in children.”

“I was sick to my stomach,” Bauer said, concerned that Kennedy would link her study to discredited theories, causing doctors and scientists to reject her far more measured work.

‘The Boy Who Cried Wolf’

Several medical and scientific associations have called for Kennedy’s removal or resignation. Many scientists are skeptical of what he says because much of it has been misleading or wrong. For example, he’s said HIV isn’t the only cause of AIDS (it is), that antidepressant drugs cause mass shootings (they don’t), that older adults don’t have severe autism (some do), that the measles vaccine causes brain swelling (it doesn’t), that covid vaccines were the deadliest vaccines ever made (they aren’t), that vaccines aren’t safety-tested (they are), and that vaccines contribute to autism (they don’t).

“This is like the boy who cried wolf,” said Brian Lee, an epidemiologist at Drexel University. “One day he might be right about something and Americans who are not prone to conspiracies won’t trust it because it’s coming from RFK’s mouth. And that could be a problem.”

What’s more, the Trump administration is eroding scientists’ ability to probe the safety of pharmaceuticals, said Robert Steinbrook, head of health research at Public Citizen, a nonprofit consumer protection group.

“Public Citizen is very supportive of research on medications that could be linked to diseases,” he said. “But it needs to be through an open process, which looks at scientific evidence, and which doesn’t cherry-pick studies to support a preconceived point of view.”

Steinbrook said the administration has undermined his confidence in the government’s ability to conduct credible work. The Food and Drug Administration has held less than a third the number of advisory committee meetings this year as it did last, meaning fewer opportunities for experts to discuss research on the risks and benefits of drugs. The Trump administration has fired hundreds of career scientists at the CDC and FDA and cut millions of dollars in research funds, including to projects studying autism.

In early September, the CDC issued an unusual contract with the Rensselaer Polytechnic Institute to analyze datasets for signs that vaccinated children were more likely to have autism. Unlike with other research initiatives, the CDC didn’t post an open call for applications in advance. This allows agency experts to review proposals and select studies best designed to answer the question at hand.

CDC researchers told KFF Health News that experts in the agency’s autism and disability group weren’t aware of the contract or asked to review the proposal. That’s important, they said, because researchers digging through data to find clues about autism must show how they’ll rule out biological and environmental exposures that muddy the results, and ensure that children have been accurately diagnosed. One researcher said, “It absolutely looks like Kennedy has subverted the grantmaking process.”

The CDC and HHS did not respond to KFF Health News’ requests for information on the grant, including through a Freedom of Information Act request.

The new vaccine study is separate from Kennedy’s autism data-science initiative, which was posted as an open call at the National Institutes of Health. “The hope is that something good comes of it, and that the government won’t cherry-pick or censor what scientists find out,” Lee said.

Bauer said she didn’t apply to be part of the initiative because of Kennedy’s outsize presence at HHS.

“I would not take his funding because it could take away from the credibility of my study,” she said, “in the same way that taking money from pharmaceutical companies does.”

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

Subscribe to KFF Health News’ free Morning Briefing.

This article first appeared on KFF Health News and is republished here under a Creative Commons Attribution-NoDerivatives 4.0 International License.

—

Previously Published on kffhealthnews.org

***

If you believe in the work we are doing here at The Good Men Project, please join us as a Premium Member today.

All Premium Members get to view The Good Men Project with NO ADS.

Need more info? A complete list of benefits is here.

On Substack? Connect with us there.
—

Photo credit: unsplash

Source link

Up Next

Chicken Caesar Wraps – SHK

Don't Miss

For People With Mental Illness, the Path to Disability Benefits Can Be Long and Difficult

Click to comment

Health

New Pee Test Could Identify Prostate Cancer

Published

2 months ago

October 4, 2025

Futurity

By Johns Hopkins University

This new approach could significantly reduce the need for invasive, often painful biopsies.

By analyzing urine samples from prostate cancer patients before and after prostate-removal surgery, as well as samples from healthy individuals, researchers identified a panel of three biomarkers—TTC3, H4C5, and EPCAM—that robustly detected the presence of prostate cancer.

These biomarkers were detectable in patients prior to surgery but were nearly absent post-surgery, confirming that they originated in prostate tissue.

The results appear in eBioMedicine.

Prostate cancer, one of the leading causes of death in men in the United States, is typically detected by blood tests to measure PSA, a protein produced by cancerous and noncancerous tissue in the prostate. In most men, a PSA level above 4.0 nanograms per milliliter is considered abnormal and may result in a recommendation for prostate biopsy, in which multiple samples of tissue are collected through small needles.

However, the PSA test is not very specific, meaning prostate biopsies are often needed to confirm a cancer diagnosis, says senior study author Ranjan Perera, director of the Center for RNA Biology at Johns Hopkins All Children’s Hospital in St. Petersburg, Florida, and a professor of oncology and neurosurgery at the Johns Hopkins University School of Medicine. In many cases, these biopsies are negative and can result in unintended complications, Perera says. PSA tests also can lead to unnecessary treatment for very low-grade prostate cancers that are very unlikely to grow and spread over a short period of time.

“This new biomarker panel offers a promising, sensitive, and specific, noninvasive diagnostic test for prostate cancer,” Perera says.

“It has the potential to accurately detect prostate cancer, reduce unnecessary biopsies, improve diagnostic accuracy in PSA-negative patients, and serve as the foundation for both laboratory-developed and in vitro diagnostic assays.”

The panel was found to be able to detect prostate cancer even when PSA was in the normal range and could distinguish prostate cancer from conditions like prostatitis (inflammation of the prostate) and an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH).

“There is a real need for non-PSA-based biomarkers for prostate cancer, and urine is quite easy to collect in the clinic,” says study coauthor Christian Pavlovich, a professor of urologic oncology at Johns Hopkins and program director for the Prostate Cancer Active Surveillance Program.

“Most urologists feel that an accurate urinary biomarker would be a valuable addition to our current diagnostic armamentarium.”

During the study, investigators studied biomarkers in urine samples from healthy individuals as well as from patients with biopsy-proven prostate cancer undergoing prostate-removal surgeries at Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, or AdventHealth Global Robotics Institute in Celebration, Florida.

They studied 341 urine specimens (107 from healthy individuals, 136 from patients with prostate cancer before surgery, and 98 after surgery) during the development of their urine test and an additional 1,055 specimens (162 from healthy individuals, 484 from patients with prostate cancer before surgery, and 409 after surgery) to validate the test.

During the performance evaluation phase of testing, the scientists also studied samples from patients with BPH or prostatitis, and healthy controls, from Johns Hopkins Hospital from 2022 to 2025.

Investigators extracted RNA from prostate cells shed in 50-ml urine samples and analyzed them using RNA sequencing and also real-time quantitative polymerase chain reaction (qPCR) to study gene expression. They also used immunohistochemistry to study biomarkers in samples from cancerous prostate tissue and healthy adjacent tissue, and statistical analyses to compare biomarkers found in the urine and tissue samples.

From an initial 815 prostate-specific genes identified in urine from men with prostate cancers, the investigators prioritized the top 50 genes, then the top nine, and from there selected the three top performers—TTC3, H4C5, and EPCAM—for further analysis.

Overall, expression levels of the three biomarkers were significantly higher in urine samples from individuals with prostate cancers than in urine from the healthy controls. The expression of each biomarker diminished to low or undetectable levels in samples taken after surgery. A greater proportion of patients with prostate cancer tested positive for the three biomarkers than for PCA3, another biomarker associated with prostate cancers, in both the development study and the validation study.

“This test has the potential to help physicians improve diagnostic accuracy of prostate cancer, reducing unnecessary interventions while allowing early treatment for those who need it,” says study coauthor Vipul Patel, director of urologic oncology at AdventHealth Cancer Institute in Celebration, Florida. Patel also is medical director of global robotics for AdventHealth’s Global Robotics Institute, and founder of the International Prostate Cancer Foundation.

“On behalf of physicians and patient globally, I advocate for further study and progress for these biomarkers.”

Investigators are considering how the biomarker panel could be used alone or combined with a PSA test to make a “super PSA,” Perera says. The next steps for the research are to have an independent trial of the test at another institution and to further develop the test for laboratory use in clinical settings, he says. The investigators have filed a patent, and Johns Hopkins Technology Ventures is helping the team to spin off a company.

Additional coauthors are from Johns Hopkins; Charles University in Prague; the University of Kansas; Orlando Health Medical Group Urology-Winter Park in Orlando, Florida; and AdventHealth Cancer Institute.

Support for the work came from the International Prostate Cancer Foundation, the Johns Hopkins Kimmel Cancer Center, the Bankhead-Coley Cancer Research Program to Perera, and by the Maryland Innovation Initiative Grant to Pavlovich and Perera.

Bettegowda is a consultant for Haystack Oncology, Privo Technologies, and Bionaut Labs. He is a cofounder of OrisDx and Belay Diagnostics.

Source: Johns Hopkins University

Original Study DOI: 10.1016/j.ebiom.2025.105895

—

Previously Published on futurity.org with Creative Commons License

***

–

The world is changing fast. We help you keep up.

We’ll send you 1 post, 3x per week.

Join The Good Men Project as a Premium Member today.

All Premium Members get to view The Good Men Project with NO ADS. Need more info? A complete list of benefits is here.

—

Photo credit: iStock

Source link

Health

How Breath Affects Your Metabolism, Digestion, and Sleep

Published

2 months ago

October 4, 2025

Brian Comly

By Niraj Naik.

Breathing is often thought of as a simple, automatic act, but its impact extends far beyond the exchange of oxygen. The way we breathe directly influences how our body processes food, produces energy, and even rests at night. By understanding how breath affects digestion, metabolism, and sleep, we can tap into a natural, non-invasive method of supporting health.

Modern research is increasingly exploring the impact of intentional breathing techniques on gut health, metabolic balance, and sleep.

The Science of Breathing and the Nervous System

Breathing acts as a primary regulator of the autonomic nervous system, which governs involuntary functions such as heart rate, hormone release, and gastrointestinal motility. Shallow, rapid breathing typically activates the sympathetic “fight-or-flight” state, while slow diaphragmatic breathing stimulates the parasympathetic “rest-and-digest” mode. This is why breathwork and the nervous system are inseparably linked: breathing patterns signal whether the body should prioritize energy conservation, digestion, or alertness.

Emerging studies show that science-backed breath training can improve vagus nerve activity, reduce stress hormones like cortisol, and optimize gastrointestinal motility¹. This connection forms the foundation of why breathwork for metabolism, digestion, and sleep is increasingly being studied in clinical contexts.

Breath as a Metabolic Regulator

Metabolism depends on efficient oxygen delivery to cells for ATP (Adenosine Triphosphate, a molecule that serves as the primary energy carrier in cells) production, the energy currency of the body. If breathing is shallow or inefficient, oxygen supply decreases, shifting energy production toward less efficient anaerobic pathways. This leads to quicker fatigue, impaired fat utilization, and sluggish energy output.

Practicing breathing exercises for metabolism enhances diaphragmatic engagement, increasing oxygen saturation and improving the body’s ability to metabolize fat for fuel. For individuals trying to sustain a consistent gym routine, combining physical training with breathwork for metabolism supports endurance and recovery by ensuring cells are well-oxygenated.

Clinical research indicates that slow-paced, deep breathing helps regulate blood glucose and improves metabolic efficiency 2. By practicing daily breathwork for metabolism, people may complement their nutrition and fitness programs, creating a minimalist routine for better health that leverages both movement and controlled breath.

Diaphragmatic Breathing & Digestive Flow

The digestive process is strongly tied to the parasympathetic nervous system. Stress or anxiety often causes shallow breathing, which impairs gastric secretions and gut motility. This explains how breath affects digestion so profoundly: relaxed breathing enhances vagal tone, improving peristalsis and nutrient absorption.

Early studies and clinical observations suggest that practicing breathwork for digestion may reduce bloating, improve bowel regularity, and support digestive enzyme activity 3. Techniques such as diaphragmatic breathing increase abdominal pressure, gently massaging internal organs, and supporting blood flow to the digestive tract.

For individuals struggling with irritable bowel syndrome (IBS) or stress-related gut issues, breathwork and the nervous system play an essential role in symptom management. Incorporating even five minutes of breathwork for digestion daily can significantly improve comfort and meal satisfaction.

How Breath Regulates Sleep

Poor breathing patterns are linked to insomnia, sleep apnea, and restless sleep cycles. Shallow breathing stimulates the sympathetic nervous system, keeping the body in a heightened state of alertness 4 . By contrast, deep nasal breathing supports relaxation and may indirectly influence sleep-promoting hormones and circadian readiness.

Techniques such as the 4-7-8 method, diaphragmatic breathing, or slow alternate nostril breathing have been validated as effective methods of breathing for better sleep. Practicing breathing exercises for metabolism during the day indirectly aids nighttime rest, as better oxygen use reduces cortisol levels and balances circadian rhythms.

Patients with sleep apnea demonstrate disrupted oxygen flow, highlighting how disordered breathing disrupts restorative rest cycles. By adopting breathing for better sleep strategies, individuals can improve both sleep onset and depth, making breathwork a cost-free complement to sleep hygiene practices. However, while breathwork may improve sleep quality in some individuals, clinical conditions such as sleep apnea require medical evaluation and treatment.

Integrating Breathwork Into Daily Life

Breathwork is most effective when woven into daily habits. For example:

Before meals: Practice 5 minutes of breathwork for digestion to prime the gut.
During workouts: Use diaphragmatic breathing to enhance oxygen efficiency and support breathwork for metabolism.
At night: End the day with breathing for better sleep to prepare the body for deep rest. Such integration creates sustainable benefits without requiring drastic lifestyle changes.

Whether one follows a structured training program or a minimalist routine for better health, the key is consistency.

Frequently Asked Questions on Breathwork

1. Can breathwork really improve my metabolism?

Evidence suggests that breathwork for metabolism can improve oxygen efficiency and cellular energy production. This may enhance fat utilization, exercise endurance, and recovery, especially when combined with a consistent fitness routine.

2. How does breathwork help digestion?

Practicing breathwork for digestion stimulates the vagus nerve, improves peristalsis, and reduces stress-related bloating. This explains how breath affects digestion directly and why relaxation-based breathing supports nutrient absorption.

3. What are the best techniques for sleep?

The most effective breathing techniques for better sleep include slow diaphragmatic breathing and the 4-7-8 method. These approaches lower heart rate, reduce cortisol, and promote relaxation before bed.

From Energy to Sleep: The Power of Intentional Breathing

Breathing may seem automatic, but the way we control it influences energy, digestion, and rest. Breathwork and the nervous system create pathways that impact everything from gut motility to mitochondrial efficiency. By incorporating breathwork for metabolism, breathwork for digestion, and breathing for better sleep into daily routines, individuals can unlock powerful improvements in overall health.

For those seeking practical and lasting results, the path does not require complex tools or expensive therapies. Instead, a minimalist routine for better health anchored in mindful breathing can provide profound, science-supported benefits.

References

1. Gerritsen, R. J. S., & Band, G. P. H. (2018). Breath of life: The respiratory vagal

stimulation model of contemplative activity. Frontiers in Human Neuroscience, 12, 397.

https://doi.org/10.3389/fnhum.2018.00397

2. Obaya, H. E., Abdeen, H. A., Salem, A. A., Shehata, M. A., Aldhahi, M. I., Muka, T.,

Marques-Sule, E., Taha, M. M., Gaber, M., & Atef, H. (2023). Effect of aerobic exercise,

slow deep breathing and mindfulness meditation on cortisol and glucose levels in

women with type 2 diabetes mellitus: A randomized controlled trial. Frontiers in

Physiology, 14, 1186546. https://doi.org/10.3389/fphys.2023.1186546

3. Liu J, Lv C, Wang W, Huang Y, Wang B, Tian J, Sun C, Yu Y. Slow, deep breathing

intervention improved symptoms and altered rectal sensitivity in patients with

constipation-predominant irritable bowel syndrome. Front Neurosci. 2022 Nov

4;16:1034547. doi: 10.3389/fnins.2022.1034547. PMID: 36408402; PMCID:

PMC9673479.

4. Cowie, M. R., Linz, D., Redline, S., & et al. (2021). Sleep disordered breathing and

cardiovascular disease: JACC state-of-the-art review. Journal of the American College

of Cardiology, 78(6), 608–624. https://doi.org/10.1016/j.jacc.2021.05.048

—

This post was previously published on Mind Body Dad.

***

If you believe in the work we are doing here at The Good Men Project, please join us as a Premium Member today.

All Premium Members get to view The Good Men Project with NO ADS.

Need more info? A complete list of benefits is here.

Photo credit: iStock

Source link

Health

The Hidden Biology of Addiction and Cancer

Published

2 months ago

October 4, 2025

Jed Diamond Ph.D

I have worked in the healthcare field for more than fifty years. I began my career working in addiction medicine. After working with men and women suffering from addictions to drugs like alcohol, heroin, and cocaine, I began to realize that addiction is not just about drugs.

We know that people can have addictive relationships with food, work, and even sex and love. In my book, Looking for Love in All the Wrong Places: Overcoming Romantic and Sexual Addictions, I say,

When we find that our romantic relationships are a series of disappointments yet continue to pursue them, we are looking for love in all the wrong places. When we are overwhelmed by our physical attraction to a new person, when the chemistry feels fantastic, and we are sure that this time we have found someone who will make us whole, we are looking for love in all the wrong places.

In the book, I also quoted Dr. Stanton Peele, an authority on addiction who reminds us,

Many of us are addicts, only we don’t know it. We turn to each other out of the same needs that drive some people to drink and others to heroin. Interpersonal addiction — love addiction — is just about the most common yet least recognized form of addiction we know.

Now Dr. Raphael Cuomo has extended our understanding of addiction even further. In his book, Crave: The Hidden Biology of Addiction and Cancer, he says,

We live in a society saturated with addiction, but not just the kind that ends in emergency rooms or interventions. This is not only about heroin, meth, or alcohol. It is about the relentless cycle of stimulation and reward that defines ordinary life. Binge eating. Compulsive phone checking. Nightly glasses of wine. Doomscrolling. Sugar, caffeine, porn, social media validation, and manufactured outrage.

I had the opportunity to interview Dr. Cuomo. I asked him questions that I thought my readers would be most interested in learning about including the following:

What first got you interested in the cancer connection and why is this connection both hidden and important?

If you were talking to a group of guys, what are some of the things you would say to them about how the book could help them?

Tell us in what ways food is a drug and what do we need to know to keep from becoming hooked?

What is “Digital Dopamine” and why is it a hidden public health problem?

You can watch my full interview with Dr. Cuomo here.

Most of has have concerns about cancer, know someone who has been diagnosed with cancer, or have fears that we ignore or obsess about. Dr. Cuomo offers a new perspective I found very helpful. He says,

We often think of cancer as a genetic accident. A cell mutates, begins to divide uncontrollably, and escapes detection. The story is partially true. But it omits the most important questions:
What makes the body permissive to that escape?
Advertisement

Why does the immune system, which identifies and eliminates abnormal cells every day, begin to miss its targets?
Why do repair systems fail to correct damaged DNA?
Why does cellular growth shift from regulated to rebellious?

In ten, information-packed chapters, Dr. Cuomo answers these and many more questions that can help us understand the biology of addiction and cancer:

Molecular Scars
The Addicted Society
Craving is Chemical
Inflammation Nation
Food as a Drug
Digital Dopamine
Nicotine, Alcohol, and the Usual Suspects?
Beyond the Individual
Biology Can Change
The New Prevention

In his concluding chapter, Dr. Cuomo says,

Prevention, as commonly understood, has struggled to match the evolving reality of cancer. Cancer involves more than external exposure. It arises from internal conditions. Disease takes hold when the body’s environment shifts toward permissiveness, inflammation becomes persistent, immune surveillance weakens, insulin signaling grows erratic, and repair mechanisms fall behind damage. These issues arise collectively, resulting from behavioral, emotional, and structural patterns repeated consistently over time.

For more information about Dr. Cuomo and his work, you can visit him here: https://raphaelcuomo.com/

You can watch my interview with Dr. Cuomo here: https://youtu.be/GLuHclBPH4U

—

This post was previously published on Menalive.com.

—